Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

XBiotech presents positive interim data for initial cohort of bermekimab pilot study

Sep. 14, 2018

Galderma Research & Development discloses RORC inverse agonists

Sep. 5, 2018

Novartis describes profile of promising BTK inhibitor LOU-064

Sep. 5, 2018

Sienna releases first-in-human study data on SNA-125 in psoriasis

Aug. 28, 2018

Zai Lab discontinues development of ZL-3101 for atopic dermatitis

Aug. 27, 2018

Preclinical data and structure described for next-generation TYK2 inhibitor PF-06826647

Aug. 24, 2018

Nuevolution reveals lead discovery program targeting inhibition of IL-17A using small molecules

Aug. 23, 2018

Phase III study of MC2-01 cream in psoriasis vulgaris meets primary and secondary endpoints

Aug. 21, 2018

Phase Ib data guide Novan's development of SB-414 for atopic dermatitis

Aug. 21, 2018

First patient treated in Escalier Biosciences' phase I/IIa study of ESR-114

Aug. 16, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...